Recent performance snapshot

Iovance Biotherapeutics (IOVA) has drawn fresh attention after recent trading, with the stock closing at US$4.11 and delivering double-digit returns over the past week, past month, and past three months.

The latest move adds to a stronger trend, with a 63.1% year to date share price return and a 130.9% total shareholder return over one year, in contrast with weaker three and five year total shareholder returns.

If you are looking beyond a single biotech story, this is a useful moment to scan for other healthcare opportunities using our screener of 34 healthcare AI stocks

With the stock up sharply over the past year, trading at US$4.11 and sitting well below some valuation estimates, the key question is whether Iovance is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 50.8% Undervalued

At a last close of $4.11 against a narrative fair value of $8.35, Iovance Biotherapeutics is framed as heavily undervalued, with that view built on ambitious growth and profitability assumptions.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Want to see what kind of revenue curve and margin uplift would need to materialize to support that valuation gap? The narrative leans on aggressive scaling, higher profitability, and a future earnings multiple that assumes investors stay very optimistic about this pipeline driven story.

Result: Fair Value of $8.35 (UNDERVALUED)

However, this upbeat narrative still hinges on successful international approvals and sustained demand for Amtagvi, and any regulatory setback or pricing pushback could quickly challenge it.

Another way to look at Iovance’s valuation

While the narrative fair value of $8.35 presents Iovance as heavily undervalued, the current P/S ratio of 6.4x offers a more measured view. It sits above the 5.5x fair ratio yet remains well below the 10.7x industry average and 28.2x peer average, indicating a mix of potential upside and valuation risk. Where do you think the multiple moves next?

Next Steps

Mixed about the bullish story and the flagged concerns? Take a closer look at the numbers, weigh the risks against the upside, and review the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your style better, so consider putting a few smart contenders on your radar using focused screeners.

• Spot potential value opportunities early by scanning companies highlighted in the screener containing 21 high quality undiscovered gems.
• Prioritise resilience by filtering for companies in the 66 resilient stocks with low risk scores that aim to keep risk levels tighter.
• Target quality balance sheets by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.